Role of Aripiprazole in treatment-resistant schizophrenia

Neuropsychiatric Disease and Treatment

Volumn 8, Issue , 2012, Pages 235-244

  Mossaheb, Nilufar ^a   Kaufmann, Rainer M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antipsychotic; Aripiprazole; Clozapine; Treatment resistant schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; BLONANSERIN; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PLACEBO; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SERTINDOLE; SULPIRIDE; ZIPRASIDONE;

AGITATION; AKATHISIA; CLINICAL PRACTICE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERPROLACTINEMIA; INSOMNIA; MANIA; METABOLIC DISORDER; MONOTHERAPY; MYOPIA; NAUSEA; PATIENT COMPLIANCE; PSYCHOSIS; QT INTERVAL; RELAPSE; REVIEW; RHABDOMYOLYSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SUICIDAL BEHAVIOR; TREATMENT RESPONSE; WEIGHT GAIN;

EID: 84930484440     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S13830     Document Type: Review

References (115)

1. World Health Organization. The Global Burden of Disease: 2004 update. Available from: http://www.who.int/healthinfo/global_burden_dis-ease/2004_report_update/en/index.html. Accessed February 16, 2012.
2. Kane JM, Correll CU. Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry. 2010;71(9): 1115-1124.
3. Conley RR, Buchanan RW. Evaluation of treatment-resistant schizophrenia. Schizophr Bull. 1997;23(4):663-674.
4. Suzuki T, Remington G, Mulsant BH, et al. Treatment resistant schizophrenia and response to antipsychotics: a review. Schizophr Res. 2011;133(1-3):54-62.
5. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789-796.
6. Mortimer AM, Singh P, Shepherd CJ, Puthiryackal J. Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world. Clin Schizophr Relat Psychoses. 2010(4);4:49-55.
7. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Schizophrenia, Second Edition. Available from: http:// psychiatryonline.org/content.aspx?bookid=28§ionid=1665359. Accessed February 16, 2012.
8. National Institute for Clinical Excellence. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care. 2009. NICE clinical guideline 82. Available from: http://guidance.nice.org.uk/CG82/NICEGuidance/ pdf/English. Accessed on February 16, 2012.
9. Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry. 1999;156(7):990-999.
10. McEvoy J P, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163(4):600-610.
11. Cipriani A, Boso M, Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev. 2009;3:CD006324.
12. Nielsen J, Damkier P, Lublin H, Taylor D. Optimizing clozapine treatment. Acta Psychiatr Scand. 2011;123(6):411-422.
13. Barnes TR, McEvedy CJ, Nelson HE. Management of treatment resistant schizophrenia unresponsive to clozapine. Br J Psychiatry. 1996;31 Suppl:31-40.
14. Lieberman JA, Stroup ST, McEvoy J P, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223.
15. Mullins DC, Obeidat NA, Cuffel BJ, Naradzay J, Loebel AD. Risk of discontinuation of atypical agents in the treatment of schizophrenia. Schizophr Res. 2008;98(1-3):8-15.
16. Lindenmayer J P, Liu-Seifert H, Kulkarni PM, et al. Medication non-adherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. J Clin Psychiatry. 2009;70(7):990-996.
17. Guo X, Fang M, Zhai J, et al. Effectiveness of maintenance treatments with atypical and typical antipsychotics in stable schizophrenia with early stage: 1-year naturalistic study. Psychopharmacology (Berl). 2011;216(4):475-484.
18. Xiang YT, Wang CY, Weng YZ, et al. Predictors of relapse in Chinese schizophrenia patients: a prospective, multi-center study. Soc Psychiatry Psychiatr Epidemiol. 2011;46(12):1325-1330.
19. Melnik T, Soares BG, Puga ME, Atallah AN. Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews. Sao Paulo Med J. 2010;128(3):141-166.
20. Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull. 2009;35(2): 443-457.
21. Taylor DM, Smith L, Gee SH, Nielsen I. Augmentation of clozapine with a second antipsychotic - a meta-analysis. Acta Psychiatr Scand. 2012;125(1):15-24.
22. Porcelli S, Balzarro B, Serretti A. Clozapine resistance: augmentation strategies. Eur Neuropsychopharmacol. 2012;22(3):165-182.
23. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302(1):381-389.
24. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol. 2002;441(3):137-140.
25. Stip E, Tourjman V. Aripiprazole in schizophrenia and schizoaffective disorder: a review. Clin Ther. 2010;32 Suppl 1:S3-S20.
26. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002;63(9):763-771.
27. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003;61(2-3):123-126.
28. Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol. 2003;6(4):325-337.
29. Pigott TA, Carson WH, Saha AR, Torbeyns A F, Stock EG, Ingenito GG. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry. 2003;64(9):1048-1056.
30. Potkin SG, Saha AR, Kukawa MJ, et al. Aripirazole, an antipsychotic with a novel mode of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003;60(7):681-690.
31. Belgamwar RB, El-Sayeh HG. Aripiprazole versus placebo for schizophrenia. Cochrane Database Syst Rev. 2011;8:CD006622.
32. Komossa K, Rummel-Kluge C, Schmid F, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2009;4:CD006569.
33. Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166(2):152-163.
34. Bhattacharjee J, El-Sayeh HG. Aripiprazole versus typical antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2008;3:CD006617.
35. Blonde L, Kan HJ, Gutterman EM, et al. Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care. J Clin Psychiatry. 2008;69(5):741-788.
36. Barak Y, Aizenberg D. Switching to aripiprazole as a strategy for weight reduction: a metaanalysis in patients suffering from schizophrenia. J Obesity. 2011;2011:898013.
37. Kane JM, Meltzer HY, Carson WH Jr, McQuade RD, Marcus RN, Sanchez R; Aripiprazole Study Group. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind comparison study versus perphenazine. J Clin Psychiatry. 2007;68(2):213-223.
38. Alvarez-Jiménez M, González-Blanch C, Crespo-Facorro B, et al. Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs. 2008;22(7):547-562.
39. Gentile S. A systematic review of quality of life and weight gain-related issues in patients treated for severe and persistent mental disorders: focus on aripiprazole. Neuropsychiatric Dis Treat. 2009;5:117-125.
40. Kessing LV, Thomsen AF, Mogensen UB, Andersen PK. Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry. 2010;197(4):266-271.
41. Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;123(2-3):225-233.
42. Chung AK, Chua SE. Effects on prolongation of Bazett's corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: a meta-analysis. J Psychopharmacol. 2011;25(5):646-666.
43. Shim JC, Shin JG, Kelly DL, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry. 2007;164(9):1404-1410.
44. Hanssens L, L'Italien G, Loze JY, Marcus RN, Pans M, Kerselaers W. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). BMC Psychiatry. 2008;8:95.
45. Azekawa T, Ohashi S, Itami A. Comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder. Neuropsychiatr Dis Treat. 2011;7:691-695.
46. Riedel M, Schennach-Wolff R, Musil R, et al. Neurocognition and its influencing factors in the treatment of schizophrenia - effects of aripiprazole, olanzapine, quetiapine and risperidone. Hum Psychopharmacol. 2010;25(2):116-125.
47. Liemburg E, Aleman A, Bous J, Hollander K, Knegtering H. An open randomized pilot trial on the differential effects of aripipra-zole versus risperidone on anhedonia and subjective well-being. Pharmacopsychiatry. 2011;44(3):109-113.
48. Schirmbeck F, Esslinger C, Rausch F, Englisch S, Meyer-Lindenberg A, Zink M. Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia. Psychol Med. 2011;41(11):2361-2373.
49. Glick ID, Poyurovsky M, Ivanova O, Koran LM. Aripiprazole in schizophrenia patients with comorbid obsessive-compulsive symptoms: an open-label study of 15 patients. J Clin Psychiatry. 2008;69(12):1856-1859.
50. Schönfelder S, Schirmbeck F, Waltereit R, Englisch S, Zink M. Aripiprazole improves olanzapine-associated obsessive compulsive symptoms in schizophrenia. Clin Neuropharmacol. 2011;34(6): 256-257.
51. Englisch S, Esslinger C, Inta D, et al. Clozapine-induced obsessive-compulsive syndromes improve in combination with aripiprazole. Clin Neuropharmacol. 2009;32(4):227-229.
52. Peters B, de Haan L. Remission of schizophrenia psychosis and strong reduction of obsessive-compulsive disorder after adding clo-zapine to aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(8):1576-1577.
53. Rocha FL, Hara C. Benefts of combining aripiprazole to clozapine: three case reports. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(6):1167-1169.
54. Zink M, Knopf U, Kuwilsky A. Management of clozapine-induced obsessive-compulsive symptoms in a man with schizophrenia. Aust N Z J Psychiatry. 2007;41(3):293-294.
55. Desarkar P, Das A, Nizamie SH. Aripiprazole-induced obsessive-compulsive disorder: a report of 2 cases. J Clin Psychopharmacol. 2007;27(3):305-306.
56. Chang KY, Wu Y F. Aripiprazole-associated rhabdomyolysis in a patient with schizophrenia. J Neuropsychiatry Clin Neurosci. 2011;23(3):E51.
57. Nair AG, Nair AG, George RJ, Biswas J, Gandhi RA. Aripiprazole induced transient myopia: A case report and review of literature. Cutan Ocul Toxicol. 2012;31(1):74-76.
58. Citrome L. A review of aripirazole in the treatment of patients with schizophrenia or bipolar I disorder. Neuropsychiatric Dis Treat. 2006;2:427-443.
59. Zacher JL, Hatchett AD. Aripiprazole-induced movement disorder. Am J Psychiatry. 2006;163(1):160-161.
60. De Schutter P, Bouckaert F, Peuskens J. Aripiprazole-induced parkin-sonism in a 64-year-old female patient diagnosed with bipolar disorder. Tijdschr Psychiatr. 2011;53(5):299-303. Dutch.
61. Ono S, Suzuki Y, Shindo M, et al. Improvement of tardive dyskinesia and dystonia associated with aripiprazole following a switch to quetiapine: case report and review of the literature. J Clin Pharm Ther. October 24, 2011. [Epub ahead of print.]
62. Desarkar P, Thakur A, Sinha VK. Aripiprazole-induced acute dystonia. Am J Psychiatry. 2006;163(6):1112-1113.
63. Henderson JB, Labbate L, Worley M. A case of acute dystonia after single dose of aripiprazole in a man with cocaine dependence. Am J Addict. 2007;16(3):244.
64. McLaren JL, Cauble S, Barnett RJ. Aripiprazole induced acute dystonia after discontinuation of a stimulant medication. J Clin Psychopharmacol. 2010;30(1):77-78.
65. Solomon S, Gupta S, Jesudasan J. Temporomandibular dislocation due to aripiprazole induced dystonia. Br J Clin Pharmacol. 2010;70(6):914-915.
66. Oommen E, Chand PK, Sharma PS. Aripiprazole-induced tardive dystonia. Prim Care Companion J Clin Psychiatry. 2006;8(6):378-379.
67. Duggal HS. Aripiprazole-induced improvement in tardive dyskinesia. Can J Psychiatry. 2003;48(11):771-772.
68. Sharma A, Ramaswamy S, Dewan VK. Resolution of ziprasidone-related tardive dyskinesia with a switch to aripiprazole. Prim Care Companion J Clin Psychiatry. 2005;7(1):36.
69. Kane JM, Barnes TR, Correll CU, et al. Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials. J Psychopharmacol. 2010;24(7):1019-1029.
70. Kane JM, Fleischhacker WW, Hansen L, Perlis R, Pikalov A 3rd, Assunção-Talbott S. Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry. 2009;70(5):627-643.
71. Furuse T, Hashimoto K. Fluvoxamine for aripiprazole-associated akathisia in patients with schizophrenia: a potential role of sigma-1 receptors. Ann Gen Psychiatry. 2010;6:11.
72. Ramaswamy S, Vijay D, William M, Sattar S P, Praveen F, Petty F. Aripiprazole possibly worsens psychosis. Int Clin Psychopharmacol. 2004;19(1):45-48.
73. Barnas ME, Hussain N, Petrides G. Treatment-emergent psychosis with aripiprazole. J Clin Psychiatry. 2005;66(10):1339.
74. Reeves RR, Mack JE. Worsening schizoaffective disorder with aripiprazole. Am J Psychiatry. 2004;161(7):1308.
75. Grover S, Sharan P, Gupta N. Aripiprazole worsens psychosis: a case report. Prim Care Companion J Clin Psychiatry. 2006;8(6):380-381.
76. Ahuja N, Lloyd AJ. Aripiprazole and worsening of psychosis: a case report. J Clin Psychiatry. 2007;68(5):805-806.
77. Ahuja N, Lloyd AJ. Worsening of psychosis in a 30 year old man with undifferentiated schizophrenia. Ann Clin Psychiatry. 2008; 20(2):113-114.
78. Kapusta ND, Mossaheb N, Barnas C, Fischer P. Aripiprazole-induced psychosis: a case report of reexposure by stepwise up-titration. J Clin Psychiatry. 2007;68(9):1445-1446.
79. Letmaier M, Painold A, Holl AK, Grohmann R, Vergin H. Severe psychotic exacerbation during combined treatment with sripiprazole/ haloperidol after prior treatment with risperidone. Int J Psychiatry Clin Pract. January 3, 2012. [Epub ahead of print.]
80. Padala PR, Wengel S P, Petty F. Manic episode during treatment with aripiprazole. Am J Psychiatry. 2007;164(1):172-173.
81. Traber R, Schneiter R, Modestin J. A case of aripiprazole-induced mania. Pharmacopsychiatry. 2007;40(1):37-38.
82. Donohue A. First manic episode in a 55-year-old man after initiation of aripiprazole. Psychiatry. 2010;7(4):37-39.
83. Benyamina A, Samalin L. Atypical antipsychotic-induced mania/ hypomania: a review of recent case reports and clinical studies. Int J Psychiatry Clin Pract. 2012;16(1):2-7.
84. Holzer L, Eap CB. Aripiprazole and suicidality. Int Clin Psychopharmacol. 2006;21(2):125-126.
85. Selvaraj V, Ramaswamy S, Sharma A, Wilson D. New-onset psychosis and emergence of suicidal ideation with aripiprazole. Am J Psychiatry. 2010;167(12):1535-1536.
86. Beers E, Loonen AJ, van Grootheest AC. Suicidal ideations and suicide attempts after starting on aripiprazole, a new antipsychotic drug. Ned Tijdschr Geneeskd. 2006;150(7):401-402. Dutch.
87. Rosenheck RA. Aripiprazole and perphenazine: no difference. J Clin Psychiatry. 2007;68(11):1812-1813.
88. Duggal HS, Mendhekar DN. High-dose aripiprazole in treatment-resistant schizophrenia. J Clin Psychiatry. 2006;67(4):674-675.
89. Hughes D, Morcos M. Use of aripiprazole in treatment resistant schizophrenia. J Psychopharmacol. 2008;22(8):927-928.
90. Jong-Yih L. Successful switch from clozapine to aripiprazole. A case report. J Clin Psychopharmacol. 2009;29(1):93-95.
91. Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007;100(1):4-22.
92. Urichuk L, Prior TI, Dursun S, Baker G. Metabolism of atypical antipsychotics: involvement of cytochrome P450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008;9(5):410-488.
93. Lim S, Pralea C, Schnitt J, Bowers MB Jr, Cooper C. Possible increased efficacy of low-dose clozapine when combined with aripiprazole. J Clin Psychiatry. 2004;65(9):1284-1285.
94. Ashton AK. Aripiprazole augmentation of clozapine: in refractory schizophrenia. Psychiatry. 2005;2(2):18-19.
95. Ziegenbein M, Sieberer M, Calliess IT, Kropp S. Combination of clozapine and aripiprazole: a promising approach in treatment-resistant schizophrenia. Aust N Z J Psychiatry. 2005;39(9):840-841.
96. Abu-Tair F, Kopitz J, Bergemann N. Clozapine augmented with aripiprazole in 5 patients with schizophrenia. J Clin Psychopharmacol. 2006;26(6):669-671.
97. Clarke LA, Lindenmayer J P, Kaushik S. Clozapine augmentation with aripiprazole for negative symptoms. J Clin Psychiatry. 2006;67(4):675-676.
98. Stoner SC, Dahmen MM, Berges A, Petry WM. Augmentation of aripiprazole with low-dose clozapine. Pharmacotherapy. 2007;27(11): 1599-1602.
99. Mossaheb N, Spindelegger C, Asenbaum S, Fischer P, Barnas C. Favorable results in treatment-resistant schizophrenic patients under combination of aripiprazole with clozapine. World J Biol Psychiatry. 2010;11(2):502-505.
100. Henderson DC, Kunkel L, Nguyen DD, et al. An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand. 2006;113(2):142-147.
101. Ziegenbein M, Wittmann G, Kropp S. Aripiprazole augmentation of clozapine in treatment-resistant schizophrenia: a clinical observation. Clin Drug Investig. 2006;26(3):117-124.
102. Karunakaran K, Tungaraza TE, Harborne GC. Is clozapine-aripiprazol combination a useful regime in the management of treatment-resistant schizophrenia? J Psychopharmacol. 2007;21(4):453-456.
103. Mitsonis CI, Dimopoulos N P, Mitropoulos PA, et al. Aripiprazole augmentation in the management of residual symptoms in clozapine treated outpatients with chronic schizophrenia: An open-label pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2): 373-377.
104. De Risio A, Pancheri A, Simonetti G, Giannarelli D, Stefanutto L, Gentile B. Add-on of aripiprazole improves outcome in clozapine-resistant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(4):1112-1116.
105. Chang JS, Ahn YM, Park HJ, et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2008;69(5):720-731.
106. Fleischhacker W W, Heikkinen ME, Olie J-P, et al. Effects of adjunctive treatment with aripirazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol. 2010;13(8):1115-1125.
107. Barbui C, Accordini S, Nose M, et al. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care. J Clin Psychopharmacol. 2011;31(3): 266-273.
108. Muscatello MR, Bruno A, Pandolfo G, et al. Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. Schizophr Res. 2011;127(1-3):93-99.
109. Benedetti A, Di Paolo A, Lastella M, et al. Augmentation of clozapine with aripiprazole in severe psychotic bipolar and schizoaffective disorders: a pilot study. Clin Pract Epidemiol Ment Health. 2010;6:30-35.
110. Englisch S, Zink M. Combined antipsychotic treatment involving clozapine and aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(6):1386-1392.
111. Lieberman JA, Safferman AZ, Pollack S, et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry. 1994;151(12): 1744-1752.
112. Meltzer HY, Bastani B, Kwon KY, Ramirez LF, Burnett S, Sharpe J. A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report. Psychopharmacology (Berl). 1989;99 Suppl:S68-S72.
113. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of effect on quality of life of second- vs frst-generation antipsychotic drugs in schizophrenia. Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63(10):1079-1087.
114. Cobo Gómez J V, Fuste G, Coronas R, et al. Combination of aripiprazole and other psychopharmacological treatments in resistant- and multi-resistant patients. Curr Drug Saf. 2008;3(3): 210-215.
115. Kane JM, Correll CU, Goff DC, et al. A multi center, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry. 2009;70(10):1348-1357.